The FDA on March 27, 2017 approved ZEJULA®, a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. ZEJULA® is marketed by Tesaro, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
